Market Cap 5.32B
Revenue (ttm) 385.69M
Net Income (ttm) -287.22M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -74.47%
Debt to Equity Ratio 3.41
Volume 414,924
Avg Vol 737,384
Day's Range N/A - N/A
Shares Out 49.24M
Stochastic %K 92%
Beta 0.47
Analysts Strong Sell
Price Target $176.83

Latest News on AXSM

Axsome Therapeutics Clocks Around 60% Topline Growth In Q1

May 5, 2025, 10:41 AM EDT - 4 weeks ago

Axsome Therapeutics Clocks Around 60% Topline Growth In Q1


Axsome: The Alzheimer's Agitation Program For AXS-05

Mar 21, 2025, 11:36 AM EDT - 2 months ago

Axsome: The Alzheimer's Agitation Program For AXS-05


Axsome Q4 Earnings: Revenues Rising, Skepticism Lingering

Feb 20, 2025, 8:15 AM EST - 3 months ago

Axsome Q4 Earnings: Revenues Rising, Skepticism Lingering


Axsome Therapeutics, Inc. (AXSM) Q4 2024 Earnings Call Transcript

Feb 18, 2025, 11:12 AM EST - 3 months ago

Axsome Therapeutics, Inc. (AXSM) Q4 2024 Earnings Call Transcript


US FDA approves Axsome Therapeutics' migraine drug

Jan 30, 2025, 3:55 PM EST - 4 months ago

US FDA approves Axsome Therapeutics' migraine drug


Axsome Therapeutics Remains A Buy Despite AXS-05's Mixed Results

Dec 31, 2024, 9:15 AM EST - 5 months ago

Axsome Therapeutics Remains A Buy Despite AXS-05's Mixed Results


Axsome Therapeutics, Inc. (AXSM) Q2 2024 Earnings Call Transcript

Aug 5, 2024, 11:20 AM EDT - 10 months ago

Axsome Therapeutics, Inc. (AXSM) Q2 2024 Earnings Call Transcript


Axsome Therapeutics: Lots Of Moving Parts

Jul 23, 2024, 4:06 AM EDT - 11 months ago

Axsome Therapeutics: Lots Of Moving Parts